An Update on the Anticancer Activity of Xanthone Derivatives: A Review

The annual number of cancer deaths continues increasing every day; thus, it is urgent to search for and find active, selective, and efficient anticancer drugs as soon as possible. Among the available anticancer drugs, almost all of them contain heterocyclic moiety in their chemical structure. Xantho...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yehezkiel Steven Kurniawan, Krisfian Tata Aneka Priyangga, Jumina, Harno Dwi Pranowo, Eti Nurwening Sholikhah, Abdul Karim Zulkarnain, Hana Anisa Fatimi, Jeffry Julianus
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
R
Accès en ligne:https://doaj.org/article/58a15a96414c4b84a701b9cb70b43fa2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:The annual number of cancer deaths continues increasing every day; thus, it is urgent to search for and find active, selective, and efficient anticancer drugs as soon as possible. Among the available anticancer drugs, almost all of them contain heterocyclic moiety in their chemical structure. Xanthone is a heterocyclic compound with a dibenzo-γ-pyrone framework and well-known to have “privileged structures” for anticancer activities against several cancer cell lines. The wide anticancer activity of xanthones is produced by caspase activation, RNA binding, DNA cross-linking, as well as P-gp, kinase, aromatase, and topoisomerase inhibition. This anticancer activity depends on the type, number, and position of the attached functional groups in the xanthone skeleton. This review discusses the recent advances in the anticancer activity of xanthone derivatives, both from natural products isolation and synthesis methods, as the anticancer agent through in vitro, in vivo, and clinical assays.